Closely-held Mati Therapeutics named Chris Muller as COO, effective immediately. Most recently Mati’s CCO, Mr. Muller’s expanded responsibilities include overseeing all operating activities; and preparing for and...
Aurinia Pharmaceuticals (NASDAQ:AUPH) appointed Dr. Robert T. Foster, CEO of Hepion Pharmaceuticals, to its board. “As the doctor who discovered voclosporin, and Aurinia’s founder, [Dr. Foster] has a wealth of...
Enzo Biochem (NYSE:ENZ) appointed its chief operating officer, Kara Cannon, to be interim CEO after Hamid Erfanian, former CEO, left the company, effective Sept. 5. Mr. Erfanian led the company through the sale of Enzo...
Sernova (TSX:SVA; OTCQB:SEOVF; FSE/XETRA:PSH) appointed Cynthia Pussinen as CEO and a member of the board, succeeding Dr. Philip Toleikis, who will serve as chief technology officer. Ms. Pussinen’s expertise spans...
Closely-held Hygieia, a provider of digital therapeutics for insulin management, hired Zoe Heineman as VP of business development. Ms. Heineman brings more than 30 years of expertise in strategic leadership, operations...
Seasoned investment banker Jed Cohen has joined Raymond James as a managing director of its healthcare investment banking practice. The strategic hire underscores the firm’s continuing commitment to expanding the sector...
PharmaJet appointed Nanette Cocero, Ph.D., a recognized leader in the global pharmaceutical industry with broad commercial and business experience coupled with an extensive clinical and scientific background, to the...
iBio (NYSEA:IBIO) appointed Martin Brenner, DVM, Ph.D., as CEO and Felipe Duran as CFO, effective immediately. Dr. Brenner will also continue to serve as iBio’s CSO, a role he has held since December 2020. The...
PharmaJet named Marie Mazur, PharmD, chairwoman of the board, replacing Ron Lowy, who had chaired the board since 2011. “Marie’s experience and leadership will be of great benefit for our company as we are accelerating...
Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) appointed Kaouthar Lbiati, M.D., as an independent director. Dr. Lbiati received a post-doctorate in clinical oncology from Gustave Roussy Institute in Paris, which is a...